Vancomycin resistance in staphylococci

doi:10.1016/S1368-7646(98)80029-0

Drug Resistance Updates

Volume 1, Issue 2, 1998, Pages 135-150

https://doi.org/10.1016/S1368-7646(98)80029-0 Get rights and content

Abstract

Recent emergence of vancomycin resistance in methicillin-resistant Staphylococcus aureus (VRSA) has posed a new threat to hospital infection control and antibiotic chemotherapy. Relatively low-level resistance of VRSA compared to that of vancomycin-resistant enterococci (VRE), and prevalence of S. aureus clinical strains heterogeneously resistant to vancomycin (hetero-VRSA), challenge the value of routine antibiotic susceptibility tests as a tool for the prediction of clinical efficacy of vancomycin therapy. This review summarizes the history of emergence of glycopeptide resistance in staphylococci and considers the mechanism of resistance in these organisms.

References (138)

FukudaH et al.
The grlA mutation in norfloxacin-resistant first-step mutants and clinical isolates of Staphyloccus aureus
J Infect Chemother
(1996)
TanakaT et al.
A retrospective study on methicillin-resistant Staphyloccus aureus clinical strains in Tokyo University Hospital
J Infect Chemother
(1995)
SongMD et al.
Evolution of an inducible penicillin-target protein in mechicillin-resistant Staphylococcus aureus by gene fusion
FEBS Letter
(1987)
ReynoldsPE et al.
Methicillin-resistant strains of Staphyloccus aureus; presence of identical additional penicillin-binding protein in all strains examined
FEMS Microbiological Letter
(1986)
HiramatsuK
Genetic basis for molecular epidemiology of MRSA
Journal of Infection and Chemotherapy
(1996)
WilsonAPR et al.
Teicoplanin-resistant coagulase-negative staphylococcus
Lancet
(1986)
ArioliV et al.
Teicoplanin-resistant coagulase-negative staphylococci
Lancet
(1987)
GrantAC et al.
Teicoplanin-resistant coagulase-negative staphylococcus
Lancet
(1986)
SanyalD et al.
Peritonitis due to vancomycin-resistant Staphylococcus epidermidis
Lancet
(1991)
BuggyBP et al.
Intraleukocytic sequestration as a cause of persistent Staphylococcus aureus peritonitis in continuous ambulatory peritoneal dialysis
Am J Med
(1984)

CasewellMW

New threats to the control of methicillin-resistant Staphylococcus aureus

J Hosp Infect

(1995)

NobleWC et al.

Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTCl2201 to Staphylococcus aureus

FEMS Microbiological Letter

(1992)

SieradzkiK et al.

A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus

FEMS Microbiological Letter

(1996)

EdmondMB et al.

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control

Annals of Int Med

(1996)

LyonB et al.

Antimicrobial resistance of Staphylococcus aureus: genetic basis

Microbiological Reviews

(1987)

HoriS et al.

Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus

Antimicrob Agents Chemother

(1993)

JevonsMP

‘Celbenin’-resistant staphylococci

British Medical Journal

(1961)

MatsuhashiM et al.

Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus

Journal of Bacteriology

(1986)

HartmanBJ et al.

Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus

Journal of Bacteriology

(1984)

UtsuiY et al.

Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

(1985)

BeckWD et al.

Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-specific DNA

Journal of Bacteriology

(1986)

HiramatsuK

Molecular evolution of MRSA

Microbiology and Immunology

(1995)

RyffelC et al.

The Staphylococcus aureus mec determinant comprises an unusual cluster of direct repeats and codes for a gene product similar to the Escherichia coli sn-glycerophosphoryl diester phosphodiesterase

Journal of Bacteriology

(1991)

KreiswirthB et al.

Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus

Science

(1993)

LaceyRW et al.

Genetic analysis of methicillin-resistant strains of Staphylococcus aureus: evidence for their evolution from a single clone

J Med Microbiol

(1973)

YoshidaT et al.

Combined use of ribotyping, PFGE typing and IS431 typing in the discrimination of nosocomial strains of methicillin-resistant Staphylococcus aureus

Microbiol Immunol

(1997)

HashimotoH et al.

A survey of Staphylococcus aureus for typing and drug-resistance in varius areas of Japan during 1992 and 1993

Japanese Journal of Antibiotics

(1994)

HiramatsuK et al.

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

Lancet

(1997)

CynamonMH et al.

Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci

Antimicrob Agents Chemother

(1982)

PallanzaR et al.

Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics

J Antimicrob Chemother

(1983)

TuazonCU et al.

Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci

Antimicrob Agents Chemother

(1984)

VerbistL et al.

In vitro activity and human pharmacokinetics of teicoplanin

Antimicrob Agents Chemother

(1984)

FainsteinV et al.

Comparative in vitro study of teichomycin A2

Antimicrob Agents Chemother

(1983)

Del BeneVE et al.

Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance

J Infect Dis

(1986)

MooreEP et al.

In vitro teicoplanin resistance in coagulase negative staphylococci from patients with endocarditis and from a cardiac surgery unit

J Antimicrob Chemother

(1988)

MaugeinJ et al.

In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients

Antimicrob Agents Chemother

(1990)

VedelG et al.

Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs

Eur J Clin Microbiol Infect Dis

(1990)

MoutonRP et al.

LY 146032: activity and resistance development in vitro

J Antimicrob Chemother

(1987)

WatanakunakornC

In vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin

Journal of Antimicrobial Chemotherapy

(1988)

WatanakunakornC

In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin

Journal of Antimicrobial Chemotherapy

(1990)

WatanakunakornC

Mode of action and in-vitro activity of vancomycin

Journal of Antimicrobial Chemotherapy

(1984)

ChomaratM et al.

Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity

J Antimicrob Chemother

(1991)

ParentiF et al.

Teichomycin, new antibiotics from Actinoplanes teichomyceticus, nov. sp. I. Description of the producer strain, fermentation studies and biological properties

J Antibiot

(1978)

GriffithRS

Vancomycin use — an historical review

J Antimicrob Chemother

(1984)

SchwalbeRS et al.

Emergence of vancomycin resistance in coagulase-negative staphylococci

New England Journal of Medicine

(1987)

SchwalbeRS et al.

Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus

J Infect Dis

(1990)

FroggattJW et al.

Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus

Antimicrob Agents Chemother

(1989)

VeachLA et al.

Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection

Journal of Clinical Microbiology

(1990)

KaatzG et al.

Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis

J Infect Dis

(1990)

ShlaesDM et al.

Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin

Clinical Infectious Diseases

(1995)

Cited by (197)

Antibiotic resistance: retrospect and prospect
2023, Degradation of Antibiotics and Antibiotic-Resistant Bacteria From Various Sources
After discovery, antibiotics changed modern medicine substantially and augmented human life expectancy by 20 years. The emergence of multidrug-resistant pathogens and the dearth of new antibiotics led to the current soaring crisis of antibiotic resistance. According to the recent O’Neill report published by The UK around 10 million people may die from infections caused by multidrug-resistant superbugs by 2050. In this regard drug discovery is one of the most related recommendations. In this chapter, an overview of antibiotics and the evolution of antibiotic resistance will be given along with some future aspects. For instance there may be a bright future to come for drug discovery, as a lot of high throughput technologies like genome editing and mining are being deployed to find the new antibacterial natural products with different bioactivities or engineered/chimeric therapeutic proteins, that is, phage endolysins, lysibodies, and enzybiotics.
Eradication of vancomycin-resistant Staphylococcus aureus on a mouse model of third-degree burn infection by melittin: An antimicrobial peptide from bee venom
2021, Toxicon
Third-degree burn infections caused by antibiotic-resistant bacteria are of high clinical concern. Chemical antibiotics are not promising in eradication of bacterial infections. In this challenging condition, antimicrobial peptides (AMPs) are recently introduced as novel promising agents to overcome the issue. Accordingly, our study aimed to evaluate the efficiency of ‘melittin’ as natural peptide in bee venom, in eradicating vancomycin resistant Staphylococcus aureus (VRSA) on a mouse model of third-degree burn infection.
In vitro pharmacological value of melittin was determined by examining its inhibitory and killing activities on VRSA isolates at different doses and time periods. The action mechanism of ‘melittin’ was evaluated by fluorescent release assay and Field Emission Scanning Electron Microscopy (FE-SEM) analyses. In vivo activity and toxicity of melittin were also examined on a mouse model of third-degree burn infection.
The Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of melittin on all isolates ranged from ‘0.125–2 μg/mL’ and ‘0.125–4 μg/mL’, respectively. Rapid antibacterial activity of melittin on VRSA isolates was demonstrated by killing kinetics assays. Fluorometric and FE-SEM analyses indicated the membranolytic effects of melittin on VRSA isolates. The colonized VRSA bacteria were eradicated by melittin at 16 μg, in a single dose. No dermal toxicity and in vivo hemolysis were observed in the examined mice.
The lack of in vivo toxicity of melittin along with its potent antibacterial activity indicated its promising therapeutic value as a topical drug against S. aureus associated third-degree burn infections.
Melittin antimicrobial peptide thin layer on bone implant chitosan-antibiotic coatings and their bactericidal properties
2021, Materials Chemistry and Physics
Antibiotics resistant bacteria and biofilm formation on bone implants are the main challenges of present treatment methods in hip or joint replacement surgeries. Recently, antimicrobial peptides (AMPs) have been widely evaluated to degrade resistant bacteria and biofilms. In the present study, chitosan and chitosan/antibiotic were coated on etched titanium specimens by spin coating method and then Melittin thin layer applied on coatings by casting method. Chitosan-Melittin double layer with Melittin higher than 0.2 μg/mL created bactericidal surface and eradicated MRSA bacteria. Melittin, higher than 0.2 μg/mL, showed a toxic effect on MC3T3 pre osteoblast cells. Whereas, coatings with a combination of oxacillin (0.16 μg/mL) and Melittin (0.05 μg/mL) were able to kill MRSA bacteria. Also, coatings with chitosan/vancomycin (0.16 μg/mL)-Melittin (0.05 μg/mL) were able to eradicate VRSA bacteria after 6 h. In conclusion, by the synergistic effect of antibiotics and Melittin, antibiotic-resistant bacterial infections and biofilm formation can be prevented without toxicity.
In Silico Drug Repurposing for MDR Bacteria: Opportunities and Challenges
2019, In Silico Drug Design: Repurposing Techniques and Methodologies
The prevalence of multidrug resistance among clinical pathogens has posed a huge challenge for healthcare providers and the scientific community. The reports of MDR pathogen related incidence are fairly common in developing and developed countries around the world. The antibiotics available for bacterial diseases are losing their efficacy against newly reported MDR strains. Virtual screening and drug repurposing offer great opportunities for new drug discovery by shortening the time involved in drug development. The availability of enormous amounts of genomic and proteomic data at the cellular and metagenomic levels presents a unique opportunity to the scientific community to trace new targets in whole cell perturbations for existing drug molecules—or adverse drug reactions—and the same may be employed to devise new strategies for mounting an all-around attack against resistant pathogens. This chapter provides a synopsis of useful online databases for drug repurposing against antibiotic resistance strains and briefly mentions the challenges of computational analysis for future improvements.
Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371
2019, Clinical Therapeutics
LCB01-0371 is a novel broad-spectrum oxazolidinone antibacterial agent under investigation for the treatment of infection by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. This study evaluated the safety, tolerability, and pharmacokinetics of LCB01-0371 after a single intravenous (IV) infusion and determined its absolute oral bioavailability at a therapeutic dose of 800 mg.
: This study was conducted in 2 parts. The first part was a single-blind, placebo-controlled, escalating single IV dose study (200, 400, 800, and 1200 mg) of LCB01-0371 via 2 different infusion regimens (250 mL over 60 min or 150 mL over 30 min) in 36 healthy male volunteers. The second part was an open-label, 2-way crossover design study in which 8 subjects were randomly assigned to 1 of 2 sequences of a single oral (800 mg) or IV (400 mg) administration of LCB01-0371. Safety assessments were conducted at regular intervals. Blood and urine were serially sampled, and drug concentrations were measured for up to 24 h to calculate pharmacokinetic parameters.
LCB01-0371 after IV administration was generally safe and well tolerated up to 800 mg regardless of the infusion regimen. Adverse events were mild, excluding nausea at the highest dose, and resolved spontaneously. After a single IV administration, LCB01-0371 exhibited linear pharmacokinetic properties over the range of 200–800 mg. The elimination t_1/2, volume of distribution, and clearance ranged from 1.48 to 1.68 h, 57.74–76.72 L, and 33.17–43.31 L/h, respectively, and they remained unchanged over the corresponding dose range. C_max, AUC_0–last, and AUC_0–∞ increased in a dose-dependent manner. The dose-normalized total exposure after single PO and IV dosing were equivalent, with 90% CIs of the geometric least squares mean ratio of 86.6%–110% for AUC_0–last and 86.6%–111% for AUC_0–∞. The dose-normalized C_max was not equivalent between oral and IV dosing, with a 90% CI of the geometric least squares mean ratio of 50.0%–105%. The absolute oral bioavailability of LCB01-0371 after a single 800-mg dose was 99.75%.
After a single IV administration, LCB01-0371 was well tolerated in healthy volunteers at doses up to 800 mg, and it exhibited linear pharmacokinetic properties. The comparable total systemic exposure between IV and oral administration supports the ability to switch administration routes without a need for dose adjustment. ClinicalTrials.gov identifier: NCT02882789.
Investigation of chitosan's antibacterial activity against vancomycin resistant microorganisms and their biofilms
2017, Carbohydrate Polymers
Vancomycin-resistant microorganisms are a hurdle that traditional antibiotics struggle to overcome. These difficulties have led to search for new solutions based on natural products. Chitosan has been recognized as an effective antibacterial agent against a vast array of microorganisms including antibiotic resistant ones. As such, this work aimed to evaluate chitosan as an alternative to traditional antibiotics in the management/control of two vancomycin-resistant microorganisms, VRSA and VREF, in planktonic and sessile settings. The results obtained showed that chitosan was highly effective in inhibiting VRSA and VREF planktonic growth and reduced VREF viable counts by 6 log CFU in 30 min. Additionally, chitosan was active upon several phases of VRSA and VREF sessile growth inhibiting adhesion, biofilm formation and dual-species biofilms at concentrations as low as 0.0125 mg/mL. In lieu of these results chitosan shows great potential as a possible alternative for the control of vancomycin-resistant microorganisms in recalcitrant wound infections.

View all citing articles on Scopus

View full text

ReviewVancomycin resistance in staphylococci

Abstract

J Infect Chemother

J Infect Chemother

FEBS Letter

FEMS Microbiological Letter

Journal of Infection and Chemotherapy

Lancet

Lancet

Lancet

Lancet

Am J Med

J Hosp Infect

FEMS Microbiological Letter

FEMS Microbiological Letter

Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control

Annals of Int Med

Antimicrobial resistance of Staphylococcus aureus: genetic basis

Microbiological Reviews

Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus

Antimicrob Agents Chemother

‘Celbenin’-resistant staphylococci

British Medical Journal

Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus

Journal of Bacteriology

Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus

Journal of Bacteriology

Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Additional DNA in methicillin-resistant Staphylococcus aureus and molecular cloning of mec-specific DNA

Journal of Bacteriology

Molecular evolution of MRSA

Microbiology and Immunology

The Staphylococcus aureus mec determinant comprises an unusual cluster of direct repeats and codes for a gene product similar to the Escherichia coli sn-glycerophosphoryl diester phosphodiesterase

Journal of Bacteriology

Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus

Science

Genetic analysis of methicillin-resistant strains of Staphylococcus aureus: evidence for their evolution from a single clone

J Med Microbiol

Combined use of ribotyping, PFGE typing and IS431 typing in the discrimination of nosocomial strains of methicillin-resistant Staphylococcus aureus

Microbiol Immunol

A survey of Staphylococcus aureus for typing and drug-resistance in varius areas of Japan during 1992 and 1993

Japanese Journal of Antibiotics

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

Lancet

Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci

Antimicrob Agents Chemother

Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics

J Antimicrob Chemother

Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci

Antimicrob Agents Chemother

In vitro activity and human pharmacokinetics of teicoplanin

Antimicrob Agents Chemother

Comparative in vitro study of teichomycin A2

Antimicrob Agents Chemother

Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance

J Infect Dis

In vitro teicoplanin resistance in coagulase negative staphylococci from patients with endocarditis and from a cardiac surgery unit

J Antimicrob Chemother

In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients

Antimicrob Agents Chemother

Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs

Eur J Clin Microbiol Infect Dis

LY 146032: activity and resistance development in vitro

J Antimicrob Chemother

In vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin

Journal of Antimicrobial Chemotherapy

In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin

Journal of Antimicrobial Chemotherapy

Mode of action and in-vitro activity of vancomycin

Journal of Antimicrobial Chemotherapy

Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity

J Antimicrob Chemother

Teichomycin, new antibiotics from Actinoplanes teichomyceticus, nov. sp. I. Description of the producer strain, fermentation studies and biological properties

J Antibiot

Vancomycin use — an historical review

J Antimicrob Chemother

Emergence of vancomycin resistance in coagulase-negative staphylococci

New England Journal of Medicine

Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus

Review
Vancomycin resistance in staphylococci